Exploring the potential association between brominated diphenyl ethers, polychlorinated biphenyls, organochlorine pesticides, perfluorinated compounds, phthalates, and bisphenol a in polycystic ovary syndrome: a case–control study by Sara J Vagi et al.
Vagi et al. BMC Endocrine Disorders 2014, 14:86
http://www.biomedcentral.com/1472-6823/14/86RESEARCH ARTICLE Open AccessExploring the potential association between
brominated diphenyl ethers, polychlorinated
biphenyls, organochlorine pesticides,
perfluorinated compounds, phthalates, and
bisphenol a in polycystic ovary syndrome:
a case–control study
Sara J Vagi1, Eduardo Azziz-Baumgartner1, Andreas Sjödin1, Antonia M Calafat1, Daniel Dumesic2,
Leonardo Gonzalez3, Kayoko Kato1, Manori J Silva1, Xiaoyun Ye1 and Ricardo Azziz2,3,4*Abstract
Background: Polycystic Ovary Syndrome (PCOS) is an endocrine-metabolic disorder that affects approximately 6-10%
of women of child-bearing age. Although preliminary studies suggest that certain pollutants may act as endocrine
disruptors in animals, little is known about their potential association with PCOS. The objective of this case-control pilot
study is to determine whether women with PCOS have higher concentrations of specific environmental contaminants
compared to women who have not developed PCOS.
Methods: Fifty-two PCOS case-patients (diagnosed using the National Institutes of Health 1990 definition) and 50
controls were recruited in 2007–2008, from an urban academic medical center in Los Angeles, CA. Brominated diphenyl
ethers, polychlorinated biphenyls (PCBs), organochlorine pesticides, and perfluorinated compounds (PFCs) were
measured in serum, and phthalates metabolites and bisphenol A (BPA) in urine.
Results: PCOS case-patients had significantly higher geometric mean (GM) serum concentrations of two PFCs:
perfluorooctanoate (PFOA) (GMcases = 4.1 μg/L, GMcontrols = 2.3 μg/L; p = 0.001) and perfluorooctane sulfonate
(PFOS) (GMcases = 8.2 μg/L, GMcontrols = 4.9 μg/L; p = 0.01), and lower urinary concentrations of monobenzyl
phthalate (mBzP) (GMcases = 7.5 μg/g creatinine, GMcontrols = 11.7 μg/g creatinine; p = 0.02). Logistic regression,
controlling for body mass index, age and race, identified an increased likelihood of PCOS in subjects with higher
serum concentrations of PFOA and PFOS (adjusted-ORs = 5.8–6.9, p < 0.05), and with lower urine concentrations
of mBzP and mono-n-butyl phthalate (mBP) (aORs = 0.14–0.25, p < 0.05).
Conclusions: Our data suggest that PCOS case-patients may differ from controls in their environmental contaminant
profile. PCOS subjects had higher serum concentrations of two PFCs, PFOA and PFOS, and lower urine concentrations
of mBP and mBzP. Future studies are needed to confirm these preliminary findings and determine if these chemicals or
their precursors may have a role in the pathogenesis of PCOS.* Correspondence: razziz@gru.edu
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Polycystic ovary syndrome (PCOS) is an endocrine-
metabolic disorder that affects approximately 6-10% of
women of child bearing age [1-4], approximately 4 mil-
lion women in the United States, and is the most fre-
quent cause of oligo-anovulatory infertility [5]. PCOS is
characterized by ovulatory dysfunction, hirsutism, or
hyperandrogenemia and is associated with insulin
resistance, hyperinsulinemia, type 2 diabetes mellitus,
and endometrial carcinoma [4,6]. The annual cost of
evaluating and providing care for PCOS to reproductive-
aged women in the United States alone exceeds $4.3
billion [7].
Some pollutants may disrupt endocrine processes, but
little is known about the effects of environmental con-
taminants on the development of PCOS. Organochlorine
pesticides (OCPs) and bisphenol A (BPA) have been pos-
tulated as potential xenohormones in women by mim-
icking estrogen action and/or antagonizing testosterone
action and potentially altering the secretions of follicle-
stimulating hormone and luteinizing hormone [8]. In
vitro and animal studies have implicated polybrominated
diphenyl ethers (PBDEs), phthalates, polychlorinated bi-
phenyls (PCBs) and BPA as endocrine disruptors [9-14].
All of these industrial chemicals can be detected in food,
water, or air, and diet is an important route of human
exposure [15].
Considering the high prevalence of PCOS, the exist-
ence of an association between exposure to environmen-
tal chemicals and disease could have significant public
health and economic impact. We investigated whether
an increase in the likelihood of being diagnosed with
PCOS may be associated with exposure to 36 PCBs, 9
OCPs, 11 PBDEs, 8 PFCs, 8 phthalates, and BPA as mea-
sured by concentrations in serum or urine.
Methods
Participants and setting
Between March 2007 and May 2008 the Center for
Androgen-related Research and Discovery at Cedars-
Sinai Medical Center (CSMC) in Los Angeles, CA re-
cruited fifty-two women with PCOS and fifty controls
through media advertisements and subspecialty clinics.
Most (>90%) of PCOS patients agreed to store blood
and urine samples for future studies. As part of the
CSMC study, controls volunteered in response to adver-
tising in the surrounding community and university for
“healthy” women aged 25–45 years. All women were
aged 18–45 years. Both PCOS patients and controls pro-
vided CSMC with information about their age, race, eth-
nicity, virilization and body mass index which are
associated with case status. Participants enrolled in the
CSMC study provided written informed consent to allow
CSMC to provide Centers for Disease Control andPrevention (CDC) with anonymized data and samples
for our nested pilot study. This study was approved by
the Internal Review Board of the Centers for Disease
Control and Prevention (CDC protocol #4918).
Exclusion criteria included concurrent pregnancy, the
use of hormonal (including oral contraceptives) or other
medications for the prior three months, diabetes, meno-
pause, and inability to provide written consent.
We defined case-patients based on the strict National
Institutes of Health 1990 criteria for PCOS, specifically
including anovulation or oligo-ovulation; clinical (i.e., a
modified Ferriman-Gallwey [mFG] hirsutism score >6)
or laboratory evidence of hyperandrogenism; and the
exclusion of related disorders (i.e. thyroid dysfunction,
hyperprolactinemia, non-classic adrenal hyperplasia,
androgen-secreting tumors, etc.), as previously described
[16]. We defined controls as healthy women with long-
term regular and predictable menstrual cycles, without
hirsutism (i.e. mFG scores of ≤2), and without clinical and
laboratory evidence of hyperandrogenism or other hormo-
nal dysfunction.
Measures, sample collection and handling
Recruited participants provided single spot urine and
blood samples at CSMC. To avoid environmental con-
tamination, participants were asked to open the urine
containers when ready to provide a sample and to avoid
touching the inside of the container. Serum samples
where obtained by venipuncture performed using
standard protocol and precautions, and the samples
drawn into one 10 ml red top Vacutainer® tube per par-
ticipant. Tubes were placed upright and blood allowed
to clot at room temperature for 60 min, after which they
were centrifuged at 3,000 rpm (~1000 g) for 10 min.
Using a disposable pipet, the serum was transferred to
CDC-provided containers (10 mL amber glass bottle
with Teflon-lined screw cap [Wheaton, Millville, NJ]
Serum vial for serum PBDE content and 2 mL Nalgene®
[Rochester, NY] cryovials for serum PFCs and lipids con-
tent). The serum PBDE vials had been previously
cleaned in a laboratory dish washer and baked at 300°C
overnight and the screw caps had been rinsed with
methanol [17]. After recapping, each container was
frozen upright in a CDC-provided cardboard storage
box at −70°C until shipping.
First morning void urine samples were collected in in-
dividually wrapped collection cups provided by the
CDC. At the time of collection participants were asked
to wash their hands with soap and water, to collect at
least 10–15 ml of urine in the cup, to not remove the
cap from the cup until ready to void, and to not touch
the inside of the cup or cap. Using a sterile disposable
plastic pipet, urine samples were transferred into prela-
beled 5 ml Nalgene® cryovials (for urinary Phthalates/
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atinine content). The urinary samples were then placed in
CDC-provided storage boxes and frozen at −20°C until
shipping.
All sample collection vials were labeled with pre-
printed bar-coded labels provided by the CDC, and the
date and time of collection was added using a perman-
ent marker. Operators used disposable powder-free ni-
trile gloves and surgical masks during sample collection
and processing, and all collection and processing supplies
were provided by the CDC to maximize the integrity of
the samples. All sample processing was performed in a
fume hood lined with aluminum foil to minimize con-
tamination by ambient dust, as PBDEs are well known
contaminants in indoor dust. The laboratory space was
further thoroughly cleaned before any laboratory work
was undertaken to minimize any dust or particulate
matter that could contaminate the samples. All samples
were shipped to the CDC on dry ice and upon arrival
stored at −70°C until the time of analysis [17].
Toxicologic analyses
Blood samples were analyzed for concentration of 36
PCBs, 9 OCPs, 11 PBDEs and 8 PFCs. Laboratory results
of blood-agent concentration included both whole
serum and lipid-adjusted concentration values of PCBs,
OCPs and BDEs and serum only for PFCs.
Analytical determination of PCBs, OCPs and PBDEs in
serum were performed by gas chromatography isotope
dilution high resolution mass spectrometry, after solid
phase extraction (SPE) and co-extracted lipid removal
techniques [17]. Total cholesterol and triglycerides were
measured using a Roche Hitachi Mod P Chemistry
Analyzer (Roche Hitachi, Basel, Switzerland), using
single-point, forced-through-zero calibration curves and
Roche colorimetric methods as described in the product
applications #11491458216 V15 (total cholesterol) and
#04843673003 V13 (total triglycerides).
The measurements of PCBs, OCPs, and PBDEs were
made in batches of twenty-four unknowns, three quality
controls and three method blanks. The method blanks
were used to track any analytical background during the
sample preparation and the final analytical results were
blank subtracted. The limits of detection (LODs) were
calculated as standard deviations (SDs) of the method
blanks analyzed in parallel with the unknowns after sub-
tracting the average blank concentration or as the in-
strumental LOD in the absence of a detectable blank
level (Additional file 1). The concentration ratio be-
tween 2,2′,4,4′,5-pentabromodipehnyl ether (BDE-99)
and 2,2′,4,4′-tetrabromodipehnyl ether (BDE-47) can
be used as an indicator of contamination during sample
collection. The median ratio (BDE-99/BDE-47) in this
study was 0.19 (range 0.10 – 0.36) which is consistentwith a metabolized pattern and hence did not indicate
contamination of indoor dust which is expected to have
a ratio close to 1 (i.e. the concentration ratio between
BDE-99 and BDE-47 in the commercial pentaBDE
product used as a flame retardant).
We measured PFCs in serum using a modification of the
on-line SPE coupled to high-performance liquid chroma-
tography (HPLC)-isotope dilution tandem mass spectrom-
etry (MS/MS) approach previously described in detail [18].
Urine samples were analyzed for 11 phthalate metab-
olites and for BPA (total concentrations) using a modifi-
cation of the on-line SPE-high performance liquid
chromatography-isotope dilution tandem mass spec-
trometry approaches described before [19,20]. Urinary
creatinine, used to adjust for the dilution of the urine,
was measured using an enzymatic reaction on a Roche




Concentrations that were below the LOD were assigned a
value equal to LOD/√2 [21]. No statistical analyses were
conducted for compounds for which the majority (>50%)
of samples had concentrations < LOD. We searched for
PBDE, PCB, OCP, phthalate metabolites, PFCs and BPA
concentrations that were significantly (p < 0.05) higher
among PCOS case-patients compared to controls using
Wilcoxon Rank-Sum.
Multivariate logistic regression analyses
We used the serum concentrations or urine concentra-
tions of the chemicals to categorize exposures to the
chemicals or their parent compounds. We split observa-
tions into tertiles based on chemical concentrations then
performed multivariable logistic regression analyses to
explore associations between the concentrations of the
chemicals (in μg/L for PFCs; lipid-adjusted for PCBs,
OCPs and PBDEs and creatinine-adjusted for phthalate
metabolites and BPA) and PCOS case status after adjust-
ing for potential confounders (i.e. age [divided into 5
categories], body mass index [BMI], and White race
[compared to all other races]). This multivariable logistic
regression model is represented as PCOS (0/1) = α + β1
(chemical concentration tertile) + β2(age) + β3(BMI) + β4
(race). Hispanic ethnicity was not significantly related to
PCOS when tested in preliminary analyses by logistic re-
gression alone or when controlling for race, BMI, or age;
therefore we did not statistically control for Hispanic
ethnicity in the final models to conserve power. Due to
the high ratio of variables in the model to study partici-
pants we calculated exact adjusted odds ratios, exact p
values, and exact confidence intervals using the network
method [22]. All statistical analyses were conducted
Table 2 Minimum, maximum, mean, median, and
interquartile range values for serum whole weight, total
lipid, cholesterol and triglycerides for cases and controls
Mean Range Median Interquartilerange
Serum
weight (g)
Cases 1.97 1.86-2.04 1.99 1.94-2.00
Controls 1.97 1.87-2.04 1.99 1.96-2.01
Total lipid
(mg/dL)
Cases 607.09 404.9-1002.8 590.3 519.48-684.98
Controls 589.82 347.8-830.2 560.4 491.05-691.53
Cholesterol
(mg/dL)
Cases 1.89 129-287 186.5 165-213
Controls 1.88 98-281 187.5 160-214
Triglycerides
(mg/dL)
Cases 114.75 37-457 96.5 67.25-138.00
Controls 99.8 24-223 77.0 58.25-135.25
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ples had serum or urine concentrations < LOD for 22
PCBs, 3OCPs, 2 phthalate metabolites, and 2 PFCs; thus,
no further analyses were conducted for these com-
pounds (Additional file 2).
Results
Comparing the 52 PCOS case-patients and 50 controls,
we observed that women with PCOS had a greater mean
BMI (OR = 1.1; 95% CI = 1.0–1.2) and were younger
(OR = 0.7; 95% CI = 0.5–0.9) than controls (Table 1).
Forty-four (85%) of 52 PCOS case-patients and 27 (54%)
controls were white, 6 (12%) case-patients and 16 (32%)
controls were Black, and two (4%) case-patients and six
(12%) controls were Asian (p = 0.003). Thirty (58%) of 52
PCOS case-patients were Hispanic compared to 37 (74%)
controls (p = 0.06). Case-patients and controls had similar
total cholesterol (median 188 mg/dL [IQR 160–213]) and
triglycerides (median 88 mg/dL [IQR 62–137]) (Table 2).
Overall, more than 50% of participants had detectable
serum or urine concentrations of 6 PBDEs, 14 PCBs, 6
OCPs, 11 phthalate metabolites, 4 PFCs, and BPA. Cor-
relations between concentration values can be found in
(Additional file 3).
Perfluorinated compounds
PCOS case-patients had perfluorooctanoate (PFOA) and
perfluorooctane sulfonate (PFOS) geometric mean serum-
concentration higher than controls (4.1 μg/L vs. 2.3 μg/L,
p = 0.001; and 8.2 μg/L vs. 4.9 μg/L, p = 0.01, respectively)
(Table 3). Participants were 6.9-fold more likely to have
PCOS if they had PFOA concentrations in the highest ter-
tile (geometric mean = 5.5 μg/L, range = 4.1–13.4 μg/L)
when compared to those in the lowest tertile (geometric
mean = 1.6 μg/L, range = 0.2–2.6 μg/L). Participants were
also 5.8-fold more likely to have PCOS if they had PFOS
concentrations in the highest tertile (geometric mean =
12.5 μg/L, range = 8.6–27.9 μg/L) (Table 4).
Polychlorinated biphenyls
Participants were 5.79-7.5 times more likely to have
PCOS if they had PCB 153, 170, 180, 183, or 196 andTable 1 Minimum, maximum, mean and standard deviation
values for body mass index (BMI, in Kg/m2) and age
(in years) at time of recruitment for cases and controls
Mean (Range) S.D. t (control–case) p-valuea
BMI Cases 32.82 (18.9-51.2) 8.32 −3.427 0.001
Controls 27.62 (17.5-47.1) 6.91
AGE Cases 28.12 (18.0-45.0) 6.04 2.673 0.009
Controls 31.84 (20.0-45.0) 7.94
ap-value comparing mean of cases to mean of controls.203 whole weight (pg/mL serum) concentrations in the
middle tertile (but not the highest tertile), when com-
pared to those in the lowest tertile (Table 4). A similar
pattern also occurred among lipid-adjusted measure-
ments of PCB 170, 180, and 196 and 203 concentrations.
PCOS case-patients had PCB180 geometric mean lipid-
adjusted concentrations (4.3 ng/g) lower than controls
(5.3 ng/g) (p = 0.04) (Table 3).
Phthalates
PCOS case-patients had monobenzyl phthalate (mBzP)
geometric mean creatinine-adjusted urine concentra-
tions (7.5 μg/g creatinine) lower than controls (11.7 μg/g
creatinine) (p = 0.02) (Table 5). After controlling for
BMI, age, and race, participants were less likely to have
PCOS if they had creatinine-adjusted urine concentra-
tions of mBzP or mono-n-butyl phthalate (mBP) in the
middle or highest tertile compared to the lowest and
mono-2-ethylhexyl phthalate (mEHP), and monoethyl
phthalate (mEP) in the middle (but not the highest) ter-
tile compared to the lowest (Table 6).
Other findings
PCOS case-patients and controls had similar geometric
mean lipid-adjusted PBDEs, and OCPs serum concen-
trations (Table 3), and urinary BPA concentrations
(Table 5), with the exception of BB153 of which con-
trols had higher concentrations than case-patients
(Table 3). After controlling for BMI, age, and ethnicity,
no increase in likelihood for PCOS was associated with
any of the measured PBDEs, OCPs, or BPA, with one
exception (Tables 4 & 6).
Discussion
Key results
Our findings suggest that increasing odds of PCOS case-
status was associated with higher serum concentrations
of two PFCs (PFOA and PFOS) and with several PCB
congeners. PFOS, PFOA, PCBs and phthalates have all
Table 3 Serum and lipid-adjusted concentrations of brominated diphenyl ethers, polychlorinated biphenyls, and persistent
organic pesticides, and perfluorinated compounds in polycystic ovary syndrome (PCOS) case-patients and controls




Compounds Case-patients Controls Case-patients Controls
Brominated (Bi-) Diphenyl Ethers
2,4,4′-tribromodiphenyl ether (PBDE28) 10.8 9.9 1.9 1.8
2,2′,4,4′-tetrabromodiphenyl ether (PBDE47) 144.5 148.6 24.9 26.5
2,2′,4.4′,5-pentabromodiphenyl ether (PBDE99) 27.5 28.8 4.7 5.1
2,2′,4,4′,6-pentabromodiphenyl ether (PBDE100) 27.8 29.8 4.8 5.3
2,2′,4,4′,5,5′-hexabromobiphenyl (BB153) 3.3 6.0 0.6 1.0a
2,2′,4,4′,5,5′-hexabromodiphenyl (PBDE153) 29.7 34.3 5.1 6.1
Polychlorinated Biphenyls
2,2′,4,4′,5-pentaCB (PCB99) 10.8 12.8 1.9 2.3
2,3,3′,4,4′-pentaCB (PCB105) 3.8 3.8 0.7 0.7
2,3′,4,4′,5-pentaCB (PCB118) 15.6 15.6 2.7 2.8
2,2′,3,4′,5,5′-hexaCB (PCB146) 4.2 5.0 0.7 0.9
2,2′,4,4′,5,5′-hexaCB (PCB153) 38.6 47.2 6.7 8.4
2,3,3′,4,4′,5-hexaCB (PCB156) 4.3 5.4 0.7 1.0
2,2′,3,4,4′,5′-hexaCB (PCB138-158) 31.5 35.7 5.4 6.4
2,2′,3,3′,4,4′,5-heptaCB (PCB170) 9.9 12.0 1.7 2.1
2,2′,3,4,4′,5,5′-heptaCB (PCB180) 25.1 29.7 4.3 5.3b
2,2′,3,4,4′,5′,6-heptaCB (PCB183) 3.8 4.4 0.7 0.8
2,2′,3,4′,5,5′,6-heptaCB (PCB187) 7.1 9.2 1.2 1.7
2,2′,3,3′,4,5,6,6′-octaCB (PCB199) 4.0 5.3 0.7 0.9
2,2′,3,3′,4,4′,5,5′-octaCB (PCB 194) 0.7 1.1 0.7 1.1
2,2′,3,3′,4,4′,5′,6-octaCB and 2,2′,3,4,4′,5,5′,6-octaCB (PCB196_203) 4.6 6.2 0.8 1.1
Persistent pesticides
Hexachlorobenzene (HCB) 53.9 51.2 9.2 9.1
β-Hexachlorocyclohexane (B-HCCH) 16.0 16.1 4.2 4.4
Oxychlordane 18.6 23.1 3.2 4.1
Trans-Nonachlor 29.6 31.9 5.1 5.7
2,2-Bis(4-chlorophenyl)-1, 1-dichloroethene (PP DDE) 1217.5 1397.2 210.2 248.7
2,2-Bis(4-chlorophenyl-1, 1, 1-trichloroethane (PP DDT) 19.0 18.1 3.3 3.2
Perfluorinated Compounds μg/L serum μg/L serum
Perfluorooctanoate (PFOA) 4.1 2.3c
Perfluorooctane sulfonate (PFOS) 8.2 4.9d
Perfluorohexane sulfonate (PFHxS) 1.1 0.7
Perfluorononanoate (PFNA) 1.2 0.9
ap = 0.02 where controls have higher BB153 levels than case-patients.
bp = 0.04 where controls have higher PCB180 levels than case-patients.
cp = 0.001 where case-patients have higher PFOA levels than controls.
dp = 0.01 where case-patients have higher PFOS levels than controls.
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linked to other reproductive outcomes. Previous epide-
miologic investigations suggest that exposure to PFCs
may increase women’s risk of early menopause [23],
thyroid disease [24], and delayed pregnancy andsubfecundity [25-27]. Exposure to certain PCBs has
been associated with other reproductive health effects
such as delayed pregnancy [28]. PCB exposure has also
been linked to increased breast cancer [29], diabetes
and thyroid disease [30] risk. This is the first
Table 4 Logistic regression for middle and highest tertile serum concentrations compared to the lowest tertile for brominated diphenyl ethers,
polychlorinated biphenyls, organochlorine pesticides, and perfluorinated compounds


















2,4,4′-tribromodiphenyl ether (PBDE28) 15 19 Middle 0.79 0.30-2.05 0.54 0.14-1.90 19 16 1.32 0.51-3.41 1.04 0.29-3.68
20 14 Highest 1.43 0.55-3.72 0.95 0.27-3.31 15 18 1.00 0.38-2.68 0.69 0.17-2.64
2,2′,4,4′-tetrabromodiphenyl
ether (PBDE47)
17 17 Middle 1.00 0.39-2.59 0.67 0.18-2.30 16 18 0.79 0.30-2.05 0.65 0.17-2.38
18 16 Highest 1.12 0.43-2.91 0.70 0.21-2.76 18 16 1.00 0.39-2.59 0.73 0.20-2.60
2,2′,4.4′,5-pentabromodiphenyl
ether (PBDE99)
18 15 Middle 1.27 0.49-3.29 1.04 0.30-3.52 17 17 0.89 0.34-2.30 1.21 0.36-4.26
17 17 Highest 1.06 0.41-2.72 0.70 0.20-2.37 17 17 0.89 0.34-2.30 0.63 0.18-2.16
2,2′,4,4′,6-pentabromodiphenyl
ether (PBDE100)
18 16 Middle 1.00 0.39-2.59 0.68 0.18-2.38 20 14 1.43 0.55-3.72 0.90 0.25-3.14
16 18 Highest 0.79 0.31-2.05 0.65 0.17-2.40 15 19 0.79 0.30-2.05 0.66 0.17-2.50
2,2′,4,4′,5,5′-hexabromobiphenyl
ether (BB153)
23 13 Middle 1.24 0.47-3.25 1.26 0.35-4.60 17 12 0.85 0.32-2.26 1.10 0.30-4.14
9 23 Highest 0.27 0.10-0.77 0.01 0.31 0.04-2.15 10 23 0.26 0.10-0.69 0.01 0.49 0.08-2.90
2,2′,4,4′,5,5′-hexabromodiphenyl
ether (PBDE153)
19 16 Middle 1.06 0.41-2.72 1.29 0.39-4.45 17 17 0.70 0.27-1.83 1.03 0.30-3.65
15 18 Highest 0.74 0.28-1.94 1.11 0.31-4.04 15 19 0.55 0.21-1.44 1.01 0.27-3.94
Polychlorinated Biphenyls
2,2′,4,4′,5-pentaCB (PCB99) 18 16 Middle 0.70 0.27-1.83 2.12 0.55-9.07 16 22 0.31 0.11-0.86 0.024 0.94 0.23-3.41
13 21 Highest 0.38 0.14-1.02 0.055 1.10 0.27-4.65 15 19 0.34 0.12-0.95 0.040 0.86 0.23-3.84
2,3,3′,4,4′-pentaCB (PCB105) 19 15 Middle 1.00 0.38-2.60 1.19 0.34-4.26 16 16 0.86 0.34-2.19 0.92 0.27-3.14
14 20 Highest 0.55 0.21-1.45 0.79 0.22-2.83 15 16 0.80 0.31-2.07 1.16 0.34-4.09
2,3′,4,4′,5-pentaCB (PCB118) 17 17 Middle 0.89 0.34-2.30 1.68 0.46-6.57 20 14 1.27 0.49-3.31 2.06 0.59-7.89
17 17 Highest 0.89 0.34-2.30 2.18 0.56-9.22 14 20 0.62 0.24-1.62 1.21 0.31-4.88
2,2′,3,4′,5,5′-hexaCB (PCB146) 17 13 Middle 1.12 0.43-2.92 4.01 0.98-19.44 0.055 15 12 0.98 0.37-2.60 3.33 0.81-15.86
14 19 Highest 0.63 0.25-1.61 2.91 0.68-14.15 14 20 0.55 0.22-1.38 2.40 0.60-10.83
2,2′,4,4′,5,5′-hexaCB (PCB153) 22 12 Middle 1.83 0.69-4.85 5.79 1.41-28.11 0.011 17 17 0.48 0.18-1.28 1.88 0.47-8.21
13 21 Highest 0.62 0.24-1.62 4.20 0.81-24.95 12 22 0.26 0.09-0.71 0.009 1.42 0.27-7.89
2,3,3′,4,4′,5-hexaCB (PCB156) 21 14 Middle 1.33 0.51-3.46 3.40 0.91-14.21 20 14 1.05 0.40-2.78 2.25 0.62-8.79
13 20 Highest 0.58 0.22-1.52 4.50 0.76-31.05 13 22 0.44 0.16-1.15 2.58 0.45-16.22
2,2′,3,4,4′,5′-hexaCB and 2,3,3′,4,4′,6-hexaCB
(PCB138-158)
20 14 Middle 1.13 0.43-2.95 2.73 0.72-11.33 18 18 0.60 0.23-1.58 1.57 0.43-6.11


















Table 4 Logistic regression for middle and highest tertile serum concentrations compared to the lowest tertile for brominated diphenyl ethers,
polychlorinated biphenyls, organochlorine pesticides, and perfluorinated compounds (Continued)
2,2′,3,3′,4,4′,5-heptaCB (PCB170) 24 10 Middle 2.70 0.99-7.33 0.051 6.88 1.71-32.96 0.003 20 13 1.30 0.49-3.40 5.13 1.24-25.16 0.020
12 22 Highest 0.61 0.23-1.62 4.04 0.64-29.31 13 21 0.52 0.20-1.36 4.97 0.78-37.25
2,2′,3,4,4′,5,5′-heptaCB (PCB180) 11 23 Middle 2.35 0.88-6.30 6.42 1.60-30.52 0.005 19 14 1.02 0.39-2.66 4.48 1.08-21.73 0.037
21 13 Highest 0.70 0.27-1.83 5.21 0.88-36.37 13 21 0.46 0.18-1.22 5.93 0.88-48.77 0.073
2,2′,3,4,4′,5′,6-heptaCB (PCB183) 22 12 Middle 1.83 0.69-4.85 4.21 1.11-18.26 0.017 21 12 1.65 0.63-4.36 3.49 0.94-14.53 0.065
13 21 Highest 0.62 0.24-1.62 3.55 0.67-21.68 13 21 0.59 0.22-1.52 2.94 0.59-16.46
2,2′,3,4′,5,5′,6-heptaCB (PCB187) 20 14 Middle 1.27 0.49-3.31 2.99 1.35-18.96 23 17 1.11 0.43-2.87 3.07 0.81-13.00
14 20 Highest 0.62 0.24-1.62 3.26 0.80-12.47 12 19 0.52 0.19-1.43 3.68 0.71-21.89
2,2′,3,3′,4,4′,5,5′-octaCB (PCB194) 17 11 Middle 1.26 0.47-3.37 3.64 0.93-16.27 0.060 19 10 1.55 0.58-4.17 3.85 1.00-17.04 0.051
13 21 Highest 0.51 0.20-1.29 3.45 0.61-22.50 11 22 0.41 0.16-1.06 2.86 0.48-19.26
2,2′,3,3′,4,5,6,6′-octaCB (PCB199) 20 13 Middle 1.23 0.47-3.21 3.04 0.83-12.59 19 11 1.43 0.54-3.72 3.89 1.00-16.80 0.054
12 21 Highest 0.46 0.17-1.20 2.04 0.43-10.71 11 21 0.43 0.16-1.12 2.31 0.48-12.61
2,2′,3,3′,4,4′,5′,6-octaCB and 2,2′,3,
4, 4′,5,5′,6-octaCB (PCB196-203)
23 11 Middle 2.09 0.78-5.59 7.50 1.72-40.29 0.004 22 13 1.41 0.53-3.72 4.19 1.07-19.09 0.038
12 22 Highest 0.54 0.21-1.44 4.67 0.78-33.23 12 22 0.45 0.17-1.21 3.28 0.56-21.38
Persistent Pesticides
Hexachlorobenzene (HCB) 18 15 Middle 1.27 0.49-3.30 3.55 0.90-16.35 15 17 0.63 0.24-1.64 1.06 0.29-3.99
17 17 Highest 1.06 0.41-2.72 2.46 0.64-10.29 16 18 0.63 0.25-1.63 1.58 0.43-6.38
β-Hexachlorocyclohexane
(B-HCCH)
20 15 Middle 2.05 0.78-5.39 3.87 0.96-18.35 22 11 2.02 0.75-5.42 3.79 0.98-17.20
16 18 Highest 1.13 0.43-2.93 2.71 0.72-11.36 13 20 0.74 0.29-1.92 2.13 0.57-8.63
Oxychlordane 18 16 Middle 0.89 0.34-2.31 2.16 0.59-8.60 19 14 1.00 0.37-2.65 3.21 0.81-14.64
15 19 Highest 0.62 0.24-1.62 2.61 0.55-14.25 14 20 0.52 0.20-1.36 2.21 0.47-11.56
Trans-Nonachlor 18 16 Middle 1.00 0.39-2.59 2.19 0.60-8.67 18 16 0.89 0.34-2.31 2.17 0.58-8.80
16 18 Highest 0.79 0.30-2.05 3.16 0.64-18.15 15 19 0.62 0.24-1.62 1.95 0.43-9.67
2,2-Bis(4-chlorophenyl)-1, 21 13 Middle 1.61 0.62-4.24 2.35 0.67-8.74 21 13 1.44 0.55-3.77 2.93 0.78-12.30
1–dichloroethene (DDE) 14 20 Highest 0.70 0.27-1.82 1.15 0.31-4.37 13 21 0.55 0.21-1.44 1.14 0.30-4.44
2,2-Bis(4-chlorophenyl-1, 1, 13 20 Middle 0.52 0.20-1.36 0.45 0.12-1.62 15 18 0.62 0.24-1.63 0.79 0.22-2.79
1-trichloroethane (DDT) 19 14 Highest 1.09 0.42-2.82 1.29 0.35-4.84 17 16 0.80 0.31-2.07 1.02 0.30-3.52
Perfluorinated compounds
PFOA 15 18 Middle 2.32 0.83-6.45 1.65 0.45-6.14
Perfluorooctanoate 28 7 Highest 11.11 3.61-34.24 0.000 6.93 1.79-29.92 0.003
PFOS 19 13 Middle 3.80 1.38-10.48 0.010 3.43 0.95-13.31 0.062


















Table 4 Logistic regression for middle and highest tertile serum concentrations compared to the lowest tertile for brominated diphenyl ethers,
polychlorinated biphenyls, organochlorine pesticides, and perfluorinated compounds (Continued)
PFHxS 16 12 Middle 2.00 0.75-5.33 0.85 0.20-3.31
Perfluorohexane sulfonate 20 14 Highest 2.14 0.84-5.44 1.20 0.35-4.07
PFNA 17 13 Middle 2.15 0.80-5.73 1.13 0.37-4.49
Perfluorononanoate 21 14 Highest 2.46 0.95-6.36 2.25 0.67-8.00
aControlling for age, BMI, and race.


















Table 5 Urinary concentrations of phthalate metabolites and bisphenol A in polycystic ovary syndrome (PCOS)
case-patients and controls













Butylbenzyl phthalate (BBzP) Monobenzyl phthalate (mBzP) 4.7 9.0 7.5 11.7a
Di-n-butyl phthalate (DBP) Mono-n-butyl phthalate (mBP) 15.3 24.8 17.7 23.2
Diethyl phthalate (DEP) Monoethyl phthalate (mEP) 103.7 138.3 181.1 195.8
Di-isodecyl phthalate (DiDP) Mono(carboxynonyl) phthalate (mCNP) 3.2 3.0 3.6 2.6
Di-isononyl phthalate (DiNP) Mono(carboxyoctyl) phthalate (mCOP) 6.7 9.0 7.8 8.4





41.5 43.2 47.9 40.4
Mono-2-ethyl-5-hydroxyhexyl phthalate
(mEHHP)
23.7 28.3 27.3 26.4
Mono-2-ethylhexyl phthalate (mEHP) 3.3 4.0 3.2 3.5
Mono-2-ethyl-5-oxohexyl phthalate (mEOHP) 14.0 17.4 16.2 16.3
Di-isobutyl phthalate (DiBP) Mono-isobutyl phthalate (miBP) 6.0 8.7 7.0 8.2
Phenols
bisphenol A (BPA) 1.6 2.1 1.6 1.9
ap = 0.02 where controls have higher mBzP urinary concentrations than case-patients.
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and serum concentrations of PFCs or PCBs.
PCOS case-patients had urinary mBzP concentration
lower than controls, and lower concentrations of mBzP,
mBP, mEHP and mEP were associated with an increased
likelihood of PCOS. Previous research suggests that
some phthalates, including di-2-ethylhexyl phthalate
(DEHP), the precursor of mEHP, have anti-androgenic
effects in animals [12]. Also, epidemiologic studies have
linked mEHP and a metabolite of di-isononyl phthalate
(DiNP) with decreased testosterone production in men
[31] and mBP, mono-isobutyl phthalate, mBzP, and the
sum of metabolites of DEHP and of DiNP with delayed
pubarche in women [32]. PCOS is characterized by
hyperandrogenemia; therefore, our results are consistent
with previous evidence of the anti-androgenic effects of
certain phthalates.
Unlike previous studies [33-35], we found no asso-
ciation between PCOS and BPA. Previous investigators
quantified serum BPA concentrations using a commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kit, whereas we measured urinary concen-
trations of this toxicant using the gold-standard detec-
tion technique, isotope dilution mass spectrometry
[20]. ELISA lacks adequate analytical selectivity and
specificity, and because matrix effects may induce
performance anomalies, ELISA is not adequate for the
quantitative determination of BPA in clinical spe-
cimens [34,36].Limitations
This study is subject to several limitations. First, our
sample size of 52 PCOS case-patients and 50 controls
may not be large enough to generate enough statistical
power to detect a difference in some of the toxicant
concentrations among PCOS case-patients and con-
trols. Similarly, the small sample size limits the possi-
bility of considering non-monotonic dose–response
relationships and some significant associations can be
chance findings due to the large number of statistical
tests.
We obtained a single spot serum and urine specimen.
Therefore, the concentrations of each toxicant represent a
snapshot of each woman’s exposure at a given time. A
single measurement design may be ineffective in detecting
an association between PCOS and pollutants that me-
tabolize quickly. For example, some of the measured ana-
lytes (such as PCBs, PBDEs, OCPs, and PFCs) persist in
the body for years, while phthalates and BPA metabolize
quickly and are eliminated from urine within a few hours
after exposure.
It is unclear whether the observed associations sug-
gest that PFOA, PFOS, and the implicated PCB conge-
ners increase risk for PCOS or whether the endocrine
milieu of the disorder alters the storage and clearance
of these chemicals, leading to increased serum mea-
surements in PCOS patients. Oligomenorrhea and
amenorrhea are common symptoms of PCOS. Thus,
PCOS cases, who menstruate less frequently compared
Table 6 Logistic regression for middle and highest tertile creatinine-adjusted urine concentrations compared to the
lowest tertile for phthalate metabolites and bisphenol A
Agent N Cases N Controls Tertile Odds ratio 95% C.I. Adjusted ORa Exact 95% C.I Exact p-value
Phthalate metabolites
mBzP 16 18 Middle 0.43 0.16-1.14 0.24 0.06-0.86 0.025
Monobenzyl phthalate 13 20 Highest 0.27 0.10-0.75 0.012 0.15 0.03-0.58 0.004
mBP 15 19 Middle 0.21 0.07-0.58 0.012 0.14 0.03-0.54 0.002
Mono-n-butyl phthalate 14 19 Highest 0.41 0.15-1.12 0.003 0.25 0.06-0.96 0.042
mEHP 11 20 Middle 0.22 0.08-0.65 0.006 0.17 0.04-0.63 0.005
Mono-2-ethylhexyl phthalate 16 17 Highest 0.87 0.34-2.21 0.91 0.26-3.19
mEP 16 18 Middle 0.27 0.10-0.75 0.012 0.12 0.02-0.48 0.001
Monoethyl phthalate 15 18 Highest 0.66 0.25-1.75 0.30 0.06-1.18
mCNP 16 19 Middle 1.00 0.39-2.59 0.80 0.23-2.71
Mono (carboxynonyl) phthalate 18 14 Highest 1.06 0.41-2.77 1.45 0.43-5.07
mCOP 18 16 Middle 2.82 1.05-7.60 0.040 2.27 0.61-8.84
Mono (carboxyoctyl) phthalate 14 18 Highest 1.45 0.55-3.85 1.58 0.46-5.55
mCPP 16 14 Middle 0.78 0.30-2.07 0.83 0.23-2.91
Mono-3-carboxypropyl phthalate 14 19 Highest 0.54 0.21-1.44 0.36 0.09-1.28
mECPP 16 17 Middle 0.95 0.36-2.45 0.78 0.22-2.73
Mono-2-ethyl-5-carboxypentyl 16 17 Highest 1.85 0.69-4.91 2.09 0.57-8.16
mEHHP 15 19 Middle 0.66 0.25-1.72 0.50 0.15-1.66
Mono-2-ethyl-5-hydroxyhexyl 16 17 Highest 1.00 0.38-2.63 1.27 0.34-4.96
mEOHP 16 17 Middle 0.94 0.36-2.45 0.88 0.27-2.87
Mono-2-ethyl-5-oxohexyl phthalate 15 18 Highest 0.84 0.32-2.18 1.07 0.29-4.00
miBP 17 17 Middle 0.58 0.22-1.54 0.56 0.16-1.91
Mono-isobutyl phthalate 12 21 Highest 0.40 0.15-1.08 0.31 0.08-1.08
Phenols
BPA 15 16 Middle 0.43 0.16-1.15 0.44 0.13-1.46
Bisphenol A 14 20 Highest 0.84 0.32-2.21 0.73 0.20-2.58
aControlling for age, BMI, and race.
Bold font highlights, for any individual agent, middle or highest tertile serum concentrations that are significantly different than the lowest tertile concentration.
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out PCOS, but higher blood-toxicant concentrations
[23]. PCBs, however, are stored mostly in adipose tissue
making amenorrhea an unlikely explanation for differ-
ences in measured exposure.
Finally, a larger proportion of case-patients were of
White race compared to controls, and PCOS patients were
younger and had significantly higher BMI than controls,
although we attempted to control for these parameters
known to be associated with case-status in the logistic re-
gression models.
Conclusions
In summary, associations between PCOS and serum
concentrations of PFOS and PFOA as well as some PCBs
were observed in this pilot study. This research highlights
the need to further substantiate the association between
PCOS and exposure to these pollutants using differentstudy designs such as including large cohorts and meas-
uring for additional confounders such as adiposity. The
relationships between environmental contaminants are
complex. Humans are exposed to many endocrine dis-
rupting chemicals at once. Some chemicals have andro-
genic effects while others have anti-androgenic effects
and for some chemicals those effects are indirect, rather
than being a direct agonist or antagonist against specific
hormone receptors. It is, therefore, difficult to evaluate
true associations between environmental contaminants
and disease. Thus, further studies are needed to explore
the potential mechanisms by which these chemicals
might contribute to the development of PCOS.Additional files
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